Managing the Risk of Drug-Induced Liver Injury

被引：9

作者：

Watkins, P. B. ^{[1
,2
,3
]}

机构：

[1] Univ N Carolina, Hamner Univ North Carolina Inst Drug Safety Sci, Chapel Hill, NC 27515 USA

[2] Univ N Carolina, Dept Med, Chapel Hill, NC USA

[3] Univ N Carolina, Sch Pharm, Dept Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 94卷 / 06期

关键词：

GENOME-WIDE; BOSENTAN; ASSOCIATION;

D O I：

10.1038/clpt.2013.182

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In clinical trials, bosentan was shown to cause significant drug-induced liver injury (DILI) in some patients. Because it is not possible to identify those at higher risk for DILI, all patients to be treated with bosentan must enroll in a program requiring documentation of liver blood testing before they can receive the drug. Because this program is costly and is perceived as onerous, a genetic test capable of identifying susceptible individuals would probably be rapidly adopted by physicians.

引用

页码：629 / 631

页数：3

共 11 条

[1]

Actelion Pharmaceuticals, 2001, BRIEF DOC TRACL BOS

[2]

[Anonymous], 2013, GUID IND CLIN PHARM

[3] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].

Channick, RN ;

Simonneau, G ;

Sitbon, O ;

Robbins, IM ;

Frost, A ;

Tapson, VF ;

Badesch, DB ;

Roux, S ;

Rainisio, M ;

Bodin, F ;

Rubin, LJ .

LANCET, 2001, 358 (9288) :1119-1123

[4] Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions [J].

Daly, Ann K. .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52, 2012, 52 :21-35

[5]

Drug-Induced Liver Injury Network, ANC STUD

[6] Association of CYP2C9*2 With Bosentan-Induced Liver Injury [J].

Markova, S. M. ;

De Marco, T. ;

Bendjilali, N. ;

Kobashigawa, E. A. ;

Mefford, J. ;

Sodhi, J. ;

Le, H. ;

Zhang, C. ;

Halladay, J. ;

Rettie, A. E. ;

Khojasteh, C. ;

McGlothlin, D. ;

Wu, A. H. B. ;

Hsueh, W-C ;

Witte, J. S. ;

Schwartz, J. B. ;

Kroetz, D. L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) :678-686

[7] Bosentan therapy for pulmonary arterial hypertension [J].

Rubin, LJ ;

Badesch, DB ;

Barst, RJ ;

Galiè, N ;

Black, CM ;

Keogh, A ;

Pulido, T ;

Frost, A ;

Roux, S ;

Leconte, I ;

Landzberg, M ;

Simonneau, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (12) :896-903

[8] Risk management strategies in the postmarketing period - Safety experience with the US and European bosentan surveillance programmes [J].

Segal, ES ;

Valette, C ;

Oster, L ;

Bouley, L ;

Edfjall, C ;

Herrmann, P ;

Raineri, M ;

Kempff, M ;

Beacham, S ;

van Lierop, C .

DRUG SAFETY, 2005, 28 (11) :971-980

[9] A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury [J].

Singer, Jonathan B. ;

Lewitzky, Steve ;

Leroy, Elisabeth ;

Yang, Fan ;

Zhao, Xiaojun ;

Klickstein, Lloyd ;

Wright, Timothy M. ;

Meyer, Joanne ;

Paulding, Charles A. .

NATURE GENETICS, 2010, 42 (08) :711-U94

[10] HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer [J].

Spraggs, Colin F. ;

Budde, Laura R. ;

Briley, Linda P. ;

Bing, Nan ;

Cox, Charles J. ;

King, Karen S. ;

Whittaker, John C. ;

Mooser, Vincent E. ;

Preston, Alaknanda J. ;

Stein, Steven H. ;

Cardon, Lon R. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :667-673

← 1 2 →